FIELD: pharmaceutics.
SUBSTANCE: group of inventions is disclosed to reduce undesirable reaction of immunosuppressive drugs for treating autoimmune diseases. There are presented: pharmaceutical composition containing iguratimod or its salt and one or more immunosuppressive agents selected from nucleic acid synthesis inhibitors (e.g., methotrexate) or steroid anti-inflammatory drugs (e.g., prednisolone), device and kit of above purpose.
EFFECT: technical result consists in reduction of hepatocellular damage and elimination of reticulocytopenia caused by said immunosuppressants.
12 cl, 5 tbl, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CRYSTALLINE FORMS OF FINGOLIMOD HYDROCHLORIDE | 2009 |
|
RU2549899C2 |
| MODIFIED RELEASE PHARMACEUTICAL COMPOSITION | 2009 |
|
RU2495666C2 |
| SOLID PHARMACEUTICAL PREPARATION OF MATRIX TYPE | 2012 |
|
RU2600797C2 |
| SOLID PHARMACEUTICAL PREPARATION OF MATRIX TYPE | 2008 |
|
RU2465916C2 |
| QUICKLY DECOMPOSING, PRESSED IN FORMS MATERIALS AND METHOD OF THEIR PREPARING | 1997 |
|
RU2189227C2 |
| METHOD OF ANTIDEMENTIA DRUG STABILISATION | 2005 |
|
RU2401125C2 |
| PHARMACEUTICAL COMPOSITIONS CONTAINING S1P RECEPTOR MODULATOR | 2007 |
|
RU2487703C2 |
| PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING RHEUMATOID ARTHRITIS, CONTAINING REBAMIPIDE | 2009 |
|
RU2496497C1 |
| PHARMACEUTICAL COMPOSITION FOR CONTROLLED RELEASE OF ACTIVE SUBSTANCES AND METHOD FOR ITS PREPARING | 2003 |
|
RU2291711C2 |
| IBUPROFEN-CONTAINING ORAL PHARMACEUTICAL FORMULATION | 2019 |
|
RU2820239C2 |
